Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Wen-Pang Su"'
Autor:
Sheng-Hung Chen, Hsueh-Chou Lai, Wen-Pang Su, Jung-Ta Kao, Po-Heng Chuang, Wei-Fan Hsu, Hung-Wei Wang, Tsung-Lin Hsieh, Hung-Yao Chen, Cheng-Yuan Peng
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2022 (2022)
Aims. Long-term risk stratification using combined liver stiffness (LS) and clinically relevant blood tests acquired at the baseline further beyond the sustained virologic response (SVR) visit for chronic hepatitis C (CHC) has not been thoroughly inv
Externí odkaz:
https://doaj.org/article/5214548ac190418186a4b35148f178ee
Autor:
Wei-Fan Hsu, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Hung-Yao Chen, Hung-Wei Wang, Guan-Tarn Huang, Cheng-Yuan Peng
Publikováno v:
BMC Gastroenterology, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Studies on temporal changes in noninvasive fibrosis indices and liver stiffness measurement (LSM) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral agents (DAAs) are limited. Methods We retrospectivel
Externí odkaz:
https://doaj.org/article/92d41d3b9efa4cdbb13e873213cefe0f
Autor:
Hung-Wei Wang, Po-Heng Chuang, Wen-Pang Su, Jung-Ta Kao, Wei-Fan Hsu, Chun-Che Lin, Guan-Tarn Huang, Jaw-Town Lin, Hsueh-Chou Lai, Cheng-Yuan Peng
Publikováno v:
Cancers, Vol 13, Iss 15, p 3758 (2021)
In the RESORCE study, regorafenib after sorafenib therapy improved survival in patients with advanced hepatocellular carcinoma (HCC). In total, 88 patients with unresectable HCC who received sorafenib–regorafenib sequential therapy were enrolled. T
Externí odkaz:
https://doaj.org/article/59d0b5b5331f4ba681f3a0128d582885
Autor:
Hung-Wei Wang, Cheng-Yuan Peng, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Ching-Hsiang Chen, Wei-Fan Hsu, Guan-Tarn Huang
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Abstract We developed an optimal noninvasive index comprising routine laboratory parameters for predicting cirrhosis in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) patients. This study included 992 CHB patients and 1,284 CHC patients who
Externí odkaz:
https://doaj.org/article/cc1029e1a2ce4eee8fc4dfff953da495
Autor:
Mei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, Chun-Yen Lin, Chia-Yen Dai, Chun-Jen Liu, Jing-Houng Wang, Jee-Fu Huang, Wen-Pang Su, Hung-Chih Yang, Kwong-Ming Kee, Ming-Lun Yeh, Po-Heng Chuang, Shih-Jer Hsu, Ching-I Huang, Jung-Ta Kao, Chieh-Chang Chen, Sheng-Hung Chen, Wen-Juei Jeng, Hwai-I Yang, Yong Yuan, Sheng-Nan Lu, I-Shyan Sheen, Chen-Hua Liu, Cheng-Yuan Peng, Jia-Horng Kao, Ming-Lung Yu, Wan-Long Chuang, Chien-Jen Chen
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological respo
Externí odkaz:
https://doaj.org/article/e8525597104945a9b652438e850135a1
Autor:
Hung-Wei Wang, Hsueh-Chou Lai, Tsung-Hui Hu, Wen-Pang Su, Sheng-Nan Lu, Chia-Hsin Lin, Chao-Hung Hung, Po-Heng Chuang, Jing-Houng Wang, Mei-Hsuan Lee, Chien-Hung Chen, Cheng-Yuan Peng
Publikováno v:
Cancers, Vol 12, Iss 5, p 1177 (2020)
Noninvasive fibrosis indices can help stratify the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving nucleos(t)ide analogue (NA) therapy. We investigated the predictive performance of on-treatment changes in
Externí odkaz:
https://doaj.org/article/189e2d961fca4b17bd4b6162dfb36e41
Autor:
Sheng-Hung Chen, Hsueh-Chou Lai, I-Ping Chiang, Wen-Pang Su, Chia-Hsin Lin, Jung-Ta Kao, Po-Heng Chuang, Wei-Fan Hsu, Hung-Wei Wang, Hung-Yao Chen, Guan-Tarn Huang, Cheng-Yuan Peng
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190455 (2018)
To compare on-treatment and off-treatment parameters acquired using acoustic radiation force impulse elastography, the Fibrosis-4 (FIB-4) index, and aspartate aminotransferase-to-platelet ratio index (APRI) in patients with chronic hepatitis C (CHC).
Externí odkaz:
https://doaj.org/article/5271cf2224eb425bb6b18817dfc5d1e5
Autor:
Sheng-Hung Chen, Cheng-Yuan Peng, Hsueh-Chou Lai, I-Ping Chang, Chiung-Ju Lee, Wen-Pang Su, Chia-Hsin Lin, Jung-Ta Kao, Po-Heng Chuang
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140554 (2015)
The aim of this study was to compare the diagnostic performances of the collagen proportionate area (CPA) and liver stiffness measurement (LSM) for liver fibrosis quantification in chronic hepatitis C (CHC).A total of 137 eligible consecutive Taiwane
Externí odkaz:
https://doaj.org/article/8fa518e11ad248378634173c53963f16
Autor:
Wei‐Fan Hsu, Hsueh‐Chou Lai, Po‐Heng Chuang, Wen‐Pang Su, Sheng‐Hung Chen, Hung‐Yao Chen, Hung‐Wei Wang, Guan‐Tarn Huang, Cheng‐Yuan Peng
Publikováno v:
Journal of viral hepatitisREFERENCES. 29(9)
Patients with chronic hepatitis C (CHC) have a higher prevalence of hepatic steatosis and dyslipidaemia than healthy individuals. We analysed noninvasive fibrosis assessments, especially nonalcoholic fatty liver disease (NAFLD)-related noninvasive fi
Autor:
Ding-Shinn Chen, Sheng-Uei Fang, Chen-Hua Liu, Wen-Pang Su, Cheng Yuan Peng, Hsueh Chou Lai, Cheng-Kuan Lin, Sheng-Shun Yang, Chun-Chao Chang, Pei-Jer Chen, Tung-Hung Su, Yu-Jen Fang, Jia-Horng Kao, Wei-Yu Kao, Chun-Jen Liu
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports
Scientific Reports
Data regarding the efficacy and tolerability of elbasvir/grazoprevir (EBR/GZR) for East-Asian hepatitis C virus genotype 1b (HCV GT1b) patients receiving hemodialysis were limited. We prospectively recruited 40 HCV GT1b hemodialysis patients who rece